shrnas against sox2 (Vector Biolabs)
Structured Review

Shrnas Against Sox2, supplied by Vector Biolabs, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/shrnas against sox2/product/Vector Biolabs
Average 94 stars, based on 2 article reviews
Images
1) Product Images from "SOX2 commands LIM homeobox transcription factors in choroid plexus development and tumorigenesis"
Article Title: SOX2 commands LIM homeobox transcription factors in choroid plexus development and tumorigenesis
Journal: Neuro-Oncology
doi: 10.1093/neuonc/noaf085
Figure Legend Snippet: SnRNA-seq reveals cellular diversity and dynamic differentiation in NOTCH-driven CP tumors characterized by a glial progenitor-like signature. (A) Major cell types of a NOTCH-driven CPP from an adult Lcre;NICD1 mouse. Uniform Manifold Approximation and Projection (UMAP) of 6428 single-nucleus profiles, colored by post hoc annotated cell type; also see . (B) UMAP showing mesenchymal, epithelial, and NOTCH-activated profiles from snRNA-seq in NOTCH-driven CPP, colored by expression of Wnt5a (mesenchymal marker, left ), Hes1 (NOTCH pathway target, middle ), and Otx2 (CP epithelial marker, right ); also see . (C) GO analysis of differentially expressed genes in the epithelial-like tumor cell compartment in NOTCH-driven CPP. (D) The expression of markers for glial progenitors in the rhombic lip in NOTCH-driven CPP. UMAP shows 6428 single-nucleus profiles from snRNA-seq in NOTCH-driven CPP, colored by expression of genes associated with glial progenitors in the rhombic lip in the hindbrain ( Rspo1 , Zfp423 , Zic3 , Msx1 , Sox2 , and Slc1a3 ). (E) Western blot analysis of MSX1 expression in the CP of wild-type mice, and NOTCH-driven CPP in Lcre;NICD1 animals ( n = 3 per genotype, mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). Data were generated from 2 independent experiments. (F) RT-qPCR analysis of Rspo1 and Gdf7 mRNA levels in NOTCH-driven CPP and wild-type CP ( n = 3 per time point per genotype, mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). Three independent experiments were conducted. (G) UMAP showing single-nucleus profiles in the epithelial-like compartment in (A) colored by subgroups; also see . (H) Cell trajectory analysis of single-nucleus profiles of subgroups of the epithelial-like compartment, and the glia-like compartment in NOTCH-driven CPP. (I) Violin plots for the expression of Rspo1 , Zfp423 , Msx1 , and Zic4 in subgroups of the epithelial-like compartment in NOTCH-driven CPP.
Techniques Used: Expressing, Marker, Western Blot, Generated, Quantitative RT-PCR
Figure Legend Snippet: Increased SOX2 expression in CP tumors in humans and mice. (A) Immunohistochemistry of SOX2 is shown in the upper rhombic lip/roof plate (red dotted lines) and hindbrain CP (arrow) in wild-type mice, NOTCH-driven CPP and CPC (arrowheads) in Lcre;NICD1 and Lcre;Ptch cko ;NICD1 animals at embryonic (E) day 14.5 (E14.5). Scale bar, 50 µm. Black dotted line marks the border of the ventricle with SOX2-expressing ependymal cells. (B) Immunofluorescence of SOX2 and OTX2 is shown in Rb1/Trp53 -deficient CPC in adult Lcre;p53 cko ;Rb cko mice. Nuclei are labeled with DAPI. Scale bar, 50 µm. (C) RT-qPCR analysis of Sox2 expression in wild-type CP, NOTCH-driven CPP, and Rb1/Trp53 -deficient CPC ( n = 5 per tissue type, mean ± SEM, 1-way ANOVA, **** P < 0.0001). (D) RNAscope of Sox2 and Myc expression in hindbrain CP (black arrow) in adult wild-type mice, and NOTCH-driven CPP (arrowhead) in adult Lcre;NICD1 animals. The dotted line marks ventricular walls with ependymal cells (red arrow). Scale bar, 50 µm. (E) Immunofluorescence of SOX2 and ARL13B is shown in NOTCH-driven CPP in adult Lcre;NICD1 animals. DAPI labels nuclei. Scale bar, 20 µm. (F) Immunofluorescence of SOX2 is shown in NOTCH-driven CP tumor cells treated with DMSO or RIN-1 (10 µM). DAPI labels nuclei. Scale bar, 50 µm. Quantification of fluorescence intensity is shown ( n = 333 [DMSO]; n = 101 [RIN-1], mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). (G) Immunohistochemistry of SOX2 in human CP tumors are shown. Scale bar, 50 µm. (CPC: n = 14; CPP and atypical CPP: n = 26). All results were obtained from 3 independent experiments. (H) RT-qPCR analysis of gene expression in human CP organoids and CP tumors ( n = 6 [CP organoid], n = 9 [CPP], n = 13 [CPC], mean ± SEM, 1-way ANOVA, * P < 0.05; ** P < 0.01; *** P < 0.001; NS, nonsignificant). (I) CosMx analysis of the expression of NOTCH1 , NOTCH2 , NOTCH3 , and SOX2 in a human CPC sample. Boxed region is shown in higher magnification on the right. (J) RNAscope studies of SOX2 and HES5 expression in a human CPP. Scale bar, 200 µm.
Techniques Used: Expressing, Immunohistochemistry, Immunofluorescence, Labeling, Quantitative RT-PCR, RNAscope, Fluorescence, Gene Expression
Figure Legend Snippet: SOX2 is essential for the glial progenitor-like signature and NOTCH-driven CP tumor development. (A) Immunofluorescence of Ki-67 is shown in NOTCH-driven CPP cells treated with control scrambled siRNAs or siRNAs against Sox2 at different concentrations. DAPI labels nuclei. Scale bar, 50 µm. Quantification of Ki-67 expression is shown ( n = 3 per group, mean ± SEM, 1-way ANOVA, **** P < 0.0001). Data were obtained from 3 independent experiments; see also . (B) Bisected brain hemispheres and hematoxylin and eosin (H&E) staining of the hindbrain CP in adult wild-type mice, and CPP in adult Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals. Red arrows point to wild-type CP, arrowheads point to CPP, black arrows point to SOX2-deficient CPP. Scale bar, 50 µm. (C) Immunofluorescence of Ki-67 and GFP is shown in CPP in Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals at day E13.5. Nuclei are labeled with DAPI. Scale bar, 50 µm. Quantification of Ki-67 expression is shown ( n = 3 per group, mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). Results were obtained from 3 independent experiments; also see . (D) Principal component analysis (PCA) of CP in wild-type mice, CPP in Lcre;NICD1 mice, and Sox2 -deficient CPP in Lcre;NICD1;Sox2 cko animals; also see . (E) Gene set enrichment analysis (GSEA) of the effect of Sox2 loss on NOTCH-driven CP tumors. Pathways regulating pluripotency of the stem cells are shown as an example; also see . NES, normalized enrichment score. FDR, false discovery rate. (F) RT-qPCR analysis of gene expression in CP in wild-type mice, and CPP from Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals ( n = 8 [CP], n = 6 [CPP], mean ± SEM, 1-way ANOVA, ** P < 0.01; *** P < 0.001; **** P < 0.0001; NS, nonsignificant); also see .
Techniques Used: Immunofluorescence, Control, Expressing, Staining, Labeling, Quantitative RT-PCR, Gene Expression
Figure Legend Snippet: SOX2 transcriptional targets in CP tumors are enriched in markers and transcriptional regulators of progenitors in the rhombic lip. (A) Pie chart illustrating the distribution of SOX2-binding sites in relation to genes in NOTCH-driven CPP in Lcre;NICD1 animals; also see . (B) Heatmap of tag densities of SOX2 (left) or H3K23Ac (right) ChIP-seq signals at all of the binding regions identified in ChIP-seq experiments. In each heat map the tag density is plotted for 10 Kb at either side of its binding peak summit. (C) Comparison of SOX2 and H3K27Ac signals generated from ChIP-seq fragment counts in the 20 Kb genomic regions surrounding SOX2 peaks in NOTCH-driven CPP. (D) Logos for the motif enriched in SOX2-binding sequences identified by motif analysis in NOTCH-driven CPP; also see . TF: transcription factor; FDR: false discovery rate. (E) Venn diagram shows the overlap of SOX2-associated genes and differentially expressed genes in NOTCH-driven CPPs at days P0 and P21, respectively. (F) GO analysis of candidate SOX2 transcriptional targets in NOTCH-driven CPP. (G) Venn diagram shows the overlap of SOX2 candidate transcriptional targets in (E) and significantly downregulated genes in Sox2 -deficient tumors. (H) Hierarchical clustering of the expression of 52 candidate SOX2 transcriptional targets identified in (G, FDR < 0.05) in wild-type CP, and Sox2 -wild-type or Sox2 -deficient NOTCH-driven CPP. Lmx1b and Hes5 on the heatmap are marked by arrows. (I) The peak density plot of fragment counts is shown in genomic regions that encompass Lmx1b , Lmx1a , Hes5 , and Zic4 , and bound by SOX2 and H3K27Ac, respectively. Genes are labeled in black with sequence in a single exon as a rectangle; also see . (J) RT-qPCR analysis of gene expression in CP in wild-type mice, and CPP from Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals ( n = 8 [CP], n = 6 [CPP], mean ± SEM, 1-way ANOVA, *** P < 0.001; **** P < 0.0001; NS, nonsignificant).
Techniques Used: Binding Assay, ChIP-sequencing, Comparison, Generated, Expressing, Labeling, Sequencing, Quantitative RT-PCR, Gene Expression
Figure Legend Snippet: SOX2 regulates transcription factors LMX1A and LMX1B in NOTCH-driven CP tumors. (A) UMAP of 6428 single-nucleus profiles from a NOTCH-driven CPP colored by Lmx1a and Lmx1b expression, respectively. (B) t-distributed stochastic neighbor embedding (t-SNE) plot shows the annotated scATAC-seq profiles of different cell populations in NOTCH-driven CPP. Different subclusters of cells are marked by different colors. (C) Violin plots show the activity of different genes in each subcluster of cells. (D) Western blot analysis of the expression of SOX2, LMX1A, and LMX1B in CP in wild-type mice, and NOTCH-driven CPP in Lcre;NICD1 animals ( n = 3 per group, mean ± SEM, 2-tailed unpaired t test, ** P < 0.01; *** P < 0.001). Three independent experiments were conducted; also see . (E, F) Immunofluorescence of LMX1A (E) and LMX1B (F) is shown in Rb1/Trp53 -deficient CPC cells infected with viruses expressing SOX2. SOX2 labels infected cells. Scale bars, 50 µm. Three independent experiments were conducted. (G) Immunofluorescence of LMX1A is shown in TP53 -deficient human CPC cells infected with viruses expressing SOX2. SOX2 labels infected cells. Scale bar, 50 µm. Three independent experiments were conducted. (H, I) Immunofluorescence of LMX1A (H) LMX1B (I) is shown in CPP in Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals at postnatal (P) day 7 (P7). Arrowheads point to tumor cells, arrows point to SOX2-deficient tumor cells. DAPI labels nuclei. Scale bars, 50 µm. Fluorescence intensity is quantified ( n = 1101 [LMX1A], n = 754 [LMX1B] for NOTCH-driven CPP cells; n = 457 [LMX1A], n = 563 [LMX1B] for Sox2 -deficient tumor cells; mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). The experiments were repeated 3 times independently; also see and . (J) RT-qPCR analysis of the expression of Lmx1a and Lmx1b in CP in wild-type mice, and CPP from Lcre;NICD1 and Lcre;NICD1;Sox2 cko animals ( n = 8 [CP], n = 6 [CPP], mean ± SEM, 1-way ANOVA, *** P < 0.001; **** P < 0.0001; NS, nonsignificant). Results were obtained from 1 experiment. (K) t-SNE plots show that motifs of LMX1A and LMX1B are enriched in tumor cell subclusters in NOTCH-driven CPP. Colors represent average gene activity score of cells in each subcluster. Dark red means high gene activity score, blue means low gene activity score.
Techniques Used: Expressing, Activity Assay, Western Blot, Immunofluorescence, Infection, Fluorescence, Quantitative RT-PCR
Figure Legend Snippet: LMX1A and LMX1B mediate SOX2 functions to support tumor cell proliferation. (A) Immunofluorescence of Ki-67 is shown in NOTCH-driven CPP treated with control scrambled siRNAs or siRNAs against Lmx1a and/or Lmx1b (40 nM). DAPI labels nuclei. Scale bar, 50 µm. Quantification of Ki-67 expression is shown ( n = 3 per group, mean ± SEM, 1-way ANOVA, ** P < 0.01). The experiments were repeated 3 times independently; also see . (B) Immunofluorescence of Ki-67 is shown in NOTCH-driven CPP treated with control scrambled siRNAs or siRNAs against Sox2 (40 nM), and infected with viruses expressing HA-tagged Lmx1a , Lmx1b , or control viruses. DAPI labels nuclei. Scale bar, 50 µm. Quantification of Ki-67 expression is shown ( n = 3 per group, mean ± SEM, 1-way ANOVA, **** P < 0.0001; NS, nonsignificant). Three independent experiments were conducted; also see . (C) Immunofluorescence of LMX1B is shown in NOTCH-driven CPP cells treated with DMSO or RIN-1 (10 µM). DAPI labels nuclei. Scale bar, 50 µm. Quantification of fluorescence intensity is shown ( n = 233 [DMSO]; n = 201 [RIN-1], mean ± SEM, 2-tailed unpaired t test, **** P < 0.0001). (D) RT-qPCR analysis of the expression of SOX2 , LMX1A , and LMX1B in human CP organoids and CP tumors ( n = 6 [CP organoid], n = 9 [CPP], n = 13 [CPC]; mean ± SEM, NS, nonsignificant). The experiments were repeated 1 time independently. (E) RNAscope studies of LMX1A and SOX2 expression in human CP tumors. Scale bar, 200 µm. (F) Immunofluorescence of LMX1A in human CP tumor samples is shown. DAPI labels nuclei. Scale bar, 50 µm. Three independent experiments were conducted. (G) RNAscope studies of LMX1A and HES5 expression in a human CPP. Scale bar, 200 µm.
Techniques Used: Immunofluorescence, Control, Expressing, Infection, Fluorescence, Quantitative RT-PCR, RNAscope

